We are a medical imaging company building advanced Artificial Intelligence for the detection of neurodegenerative diseases.

Our Goal

We believe a better future for Alzheimer’s patients starts with the ability to diagnose it early on

Today, there is no way to make a definitive early diagnosis of Alzheimer’s disease.

RetiSpec is on track to provide a new way to detect the disease early; providing clarity to patients and their loved ones as well as new ways for clinicians and researchers to determine what treatments are effective.

Impact

Retispec is a revolutionary non-invasive tool for early affordable detection of Alzheimer’s Disease.

RetiSpec uses hyperspectral camera technology combined with AI that non-invasively looks for distinctive signs of Alzheimer’s as well as multiple other diseases like Parkinson’s, Vascular Dementia, and ALS.

If we can diagnose faster, we can treat it better, and help to find a cure sooner.

Testimonials

Dr. Sharon Cohen, MD, FRCPC

Medical Director & Behavioural Neurologist, Toronto Memory Program

“I am impressed with the potential of their hyperspectral imaging technology to support early diagnosis of Alzheimer’s disease in a manner that is affordable and scalable. The RetiSpec team is innovative, collaborative, and pragmatic, and is moving AD biomarker science forward in an exciting direction. Retinal imaging holds promise for clinicians, patients, and those involved in drug development to pre-screen and/or predict cerebral amyloidosis in a non-invasive manner within the clinic setting.”